Welcome to our dedicated page for Myomo news (Ticker: MYO), a resource for investors and traders seeking the latest updates and insights on Myomo stock.
Myomo Inc. develops and markets wearable medical robotics for people with neurological disorders and upper-limb paralysis. Its MyoPro product line is a powered upper-limb orthosis that uses non-invasive EMG sensors to support weakened or paralyzed arms in patients with conditions such as stroke, brachial plexus injury, traumatic brain injury, spinal cord injury and other neuromuscular disease or injury.
Company news commonly covers MyoPro orders, insurance authorizations, patient-pipeline trends, revenue from recurring patient sources, market-access relationships with orthotics and prosthetics providers, and product-development updates such as the Myomo Mobile App. Updates also include clinical research evaluating MyoPro, operating results, direct-billing activity, international sales channels and board governance changes.
Myomo, Inc. (NYSE American: MYO) announced that Medicare Part B beneficiaries are receiving lump sum reimbursements for MyoPros, a wearable medical robotics offering increased functionality for those with neurological disorders and upper-limb paralysis. CMS has remitted payments based on published rates, effective April 1, 2024, through their regional contractors known as DME MACs. The company is pleased with the equitable access to this technology and the interest from clinical providers in the orthotics and prosthetics industry.
Myomo, a wearable medical robotics company, will report financial results for the first quarter ended March 31, 2024 on May 8, 2024. The Company will host a conference call on the same day with prepared remarks by its executives. Participants can pre-register for the call to gain immediate access.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.